nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Palpitations—Mycophenolic acid—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Apraclonidine—Dysgeusia—Lisinopril—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Apraclonidine—Discomfort—Leflunomide—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Apraclonidine—Skin disorder—Azathioprine—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Apraclonidine—Nervousness—Lisinopril—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Apraclonidine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Apraclonidine—Dry mouth—Leflunomide—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Apraclonidine—Vomiting—Pentoxifylline—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Apraclonidine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Apraclonidine—Headache—Pentoxifylline—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Apraclonidine—Face oedema—Prednisone—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Apraclonidine—Feeling abnormal—Captopril—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Apraclonidine—Chest pain—Mycophenolic acid—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Apraclonidine—Myalgia—Mycophenolic acid—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Apraclonidine—Infection—Leflunomide—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Apraclonidine—Vision blurred—Lisinopril—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Captopril—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Asthenia—Mometasone—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Irritability—Prednisone—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Apraclonidine—Discomfort—Mycophenolic acid—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Apraclonidine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Apraclonidine—Pruritus—Mometasone—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Apraclonidine—Ill-defined disorder—Lisinopril—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Apraclonidine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Apraclonidine—Skin disorder—Leflunomide—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Apraclonidine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Apraclonidine—Abdominal pain—Captopril—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Apraclonidine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Apraclonidine—Oedema—Mycophenolic acid—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Apraclonidine—Nausea—Pentoxifylline—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Apraclonidine—Malaise—Lisinopril—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Apraclonidine—Infection—Mycophenolic acid—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Apraclonidine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Apraclonidine—Diarrhoea—Mometasone—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Apraclonidine—Syncope—Lisinopril—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Apraclonidine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Apraclonidine—Palpitations—Lisinopril—systemic scleroderma	0.002	0.002	CcSEcCtD
Apraclonidine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.002	0.002	CcSEcCtD
Apraclonidine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Apraclonidine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Apraclonidine—Insomnia—Leflunomide—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Apraclonidine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Apraclonidine—Paraesthesia—Leflunomide—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Apraclonidine—Myalgia—Lisinopril—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Apraclonidine—Chest pain—Lisinopril—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Apraclonidine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Apraclonidine—Dyspnoea—Leflunomide—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Apraclonidine—Discomfort—Lisinopril—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Apraclonidine—Vomiting—Mometasone—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Apraclonidine—Dry mouth—Lisinopril—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Apraclonidine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Apraclonidine—Asthenia—Captopril—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Apraclonidine—Dermatitis—Mometasone—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Apraclonidine—Headache—Mometasone—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Apraclonidine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Apraclonidine—Fatigue—Leflunomide—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Apraclonidine—Oedema—Lisinopril—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Apraclonidine—Pruritus—Captopril—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Apraclonidine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Apraclonidine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Apraclonidine—Constipation—Leflunomide—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Apraclonidine—Pain—Leflunomide—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Apraclonidine—Infection—Lisinopril—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Apraclonidine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Apraclonidine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Apraclonidine—Abdominal pain—Azathioprine—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Apraclonidine—Skin disorder—Lisinopril—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Apraclonidine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Apraclonidine—Diarrhoea—Captopril—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Apraclonidine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Apraclonidine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Apraclonidine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Apraclonidine—Nausea—Mometasone—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Apraclonidine—Pain—Mycophenolic acid—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Apraclonidine—Constipation—Mycophenolic acid—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Apraclonidine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Apraclonidine—Dizziness—Captopril—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Apraclonidine—Abdominal pain—Leflunomide—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Apraclonidine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Apraclonidine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Apraclonidine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Apraclonidine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Apraclonidine—Insomnia—Lisinopril—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Apraclonidine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Apraclonidine—Paraesthesia—Lisinopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Apraclonidine—Vomiting—Captopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Apraclonidine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Apraclonidine—Dyspnoea—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Apraclonidine—Dermatitis—Captopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Apraclonidine—Somnolence—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Apraclonidine—Headache—Captopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Apraclonidine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Apraclonidine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Apraclonidine—Infection—Mycophenolate mofetil—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Apraclonidine—Fatigue—Lisinopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Apraclonidine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Apraclonidine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Apraclonidine—Pain—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Apraclonidine—Constipation—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Apraclonidine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Apraclonidine—Diarrhoea—Azathioprine—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Apraclonidine—Nausea—Captopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Apraclonidine—Asthenia—Leflunomide—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Apraclonidine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Apraclonidine—Pruritus—Leflunomide—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Apraclonidine—Dizziness—Azathioprine—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Apraclonidine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Apraclonidine—Diarrhoea—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Apraclonidine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Apraclonidine—Abdominal pain—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Apraclonidine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Apraclonidine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Apraclonidine—Vomiting—Azathioprine—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Dermatitis—Azathioprine—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Apraclonidine—Headache—Azathioprine—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Apraclonidine—Dizziness—Leflunomide—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Apraclonidine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Apraclonidine—Pain—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Apraclonidine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Apraclonidine—Vomiting—Leflunomide—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Apraclonidine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Apraclonidine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Apraclonidine—Dermatitis—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Apraclonidine—Nausea—Azathioprine—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Apraclonidine—Headache—Leflunomide—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Apraclonidine—Erythema—Prednisone—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Apraclonidine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Apraclonidine—Asthenia—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Apraclonidine—Pruritus—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Apraclonidine—Vomiting—Mycophenolic acid—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Apraclonidine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Apraclonidine—Headache—Mycophenolic acid—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Apraclonidine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Apraclonidine—Nausea—Leflunomide—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Apraclonidine—Diarrhoea—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Apraclonidine—Dizziness—Lisinopril—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Apraclonidine—Nausea—Mycophenolic acid—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Apraclonidine—Malaise—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Apraclonidine—Syncope—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Apraclonidine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Apraclonidine—Vomiting—Lisinopril—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Apraclonidine—Dermatitis—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Apraclonidine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Apraclonidine—Headache—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Apraclonidine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Apraclonidine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Apraclonidine—Nausea—Lisinopril—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Apraclonidine—Oedema—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Apraclonidine—Infection—Prednisone—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Apraclonidine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Apraclonidine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Apraclonidine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Apraclonidine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.001	0.001	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—systemic scleroderma	0.000993	0.000993	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—systemic scleroderma	0.000986	0.000986	CcSEcCtD
Apraclonidine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000962	0.000962	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—systemic scleroderma	0.000957	0.000957	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—systemic scleroderma	0.000957	0.000957	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000951	0.000951	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—systemic scleroderma	0.000947	0.000947	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—systemic scleroderma	0.000946	0.000946	CcSEcCtD
Apraclonidine—Constipation—Prednisone—systemic scleroderma	0.000939	0.000939	CcSEcCtD
Apraclonidine—Infection—Methotrexate—systemic scleroderma	0.000912	0.000912	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—systemic scleroderma	0.0009	0.0009	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000898	0.000898	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—systemic scleroderma	0.000891	0.000891	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—systemic scleroderma	0.000868	0.000868	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000836	0.000836	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—systemic scleroderma	0.00083	0.00083	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—systemic scleroderma	0.000818	0.000818	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—systemic scleroderma	0.000816	0.000816	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—systemic scleroderma	0.000809	0.000809	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000792	0.000792	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—systemic scleroderma	0.000791	0.000791	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—systemic scleroderma	0.000788	0.000788	CcSEcCtD
Apraclonidine—Pain—Methotrexate—systemic scleroderma	0.000785	0.000785	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—systemic scleroderma	0.000751	0.000751	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00075	0.00075	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—systemic scleroderma	0.000726	0.000726	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—systemic scleroderma	0.000698	0.000698	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Apraclonidine—Headache—Prednisone—systemic scleroderma	0.000688	0.000688	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000676	0.000676	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—systemic scleroderma	0.000658	0.000658	CcSEcCtD
Apraclonidine—Nausea—Prednisone—systemic scleroderma	0.000652	0.000652	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—systemic scleroderma	0.000649	0.000649	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—systemic scleroderma	0.000607	0.000607	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—systemic scleroderma	0.000583	0.000583	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Apraclonidine—Headache—Methotrexate—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—systemic scleroderma	0.000545	0.000545	CcSEcCtD
